Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.
EP. 1: Treatment Options for Non-Metastatic Castration-Resistant Prostate Cancer
Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
EP. 2: Next-Generation Androgen Receptor Inhibitors in nmCRPC
A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.
EP. 3: Adverse Events with Next-Generation Androgen Receptor Inhibitors in nmCRPC
Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.
EP. 4: Updated Safety Data and Treatment Selection in nmCRPC
Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.
EP. 5: Comorbidities, Adherence and Dose Alterations in nmCRPC
A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.
EP. 6: Quality of Life Data and Patient Preference in nmCRPC
Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.
EP. 7: Unmet Needs in nmCRPC
Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.
EP. 8: Recap: Recent Updates in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.
2 Clarke Drive Cranbury, NJ 08512